Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Mondobiotech Holding AG Basel (RLFTF) Message Board

Let's get real... Covid-19 affects way more than t

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 653
(Total Views: 264)
Posted On: 11/06/2020 10:17:16 PM
Avatar
Posted By: JLang
Re: mc67 #156
Let's get real... Covid-19 affects way more than the lungs. There are multiple, safe treatments for thrombisis. Nothing approved for kidney or liver issues (in fact, Remdesivir only makes them worse). Nothing approved for nervous system/brain, pancreas, thyroid, possibly other organ systems. These are all hallmarks of Covid19, but the lungs have a very visible pathology and so get top billing.

So what percentage of severe Covid19 patients present primarily with lung issues? The FDA has indicated it isn't interested in mild/moderate therapies, so at best, we're looking at a subset of the 15% of those considered severe and hospitalized. Let's be generous and say 12%.

Known cases are somewhere in the 10 million area, odds are high that there are at least double and probably more for actual cases in the US... the asymptomatic infected feature heavily, if not visibly with Covid19. Let's ballpark and say 300 million Americans still could be infected, and of those, about 38 million would be candidates for Aviptadil.

Now let's look at the business side of things... Relief has 2,400,000,***000*** shares on the US OTC markets... You read that right, boys and girls, 2.4 Billion with a B shares outstanding, just in the US! Microsoft has 7 Billion shares outstanding, by way of comparison. Google a mere 400 million. (Relief is no Microsoft or Google.) But let's look at the Swiss market... the swiss exchange notes for RLF there are:

Number in issue
2'660'068'581

Quite a few, but what does this mean?

It means that, for the stock to get over $1 and stay there, this company would have to earn ***several hundred million *** in profits.

"Well," you say.. "38 million patients in the US, that's a lot! Surely this stock will be worth $10 soon!"

For this stock to justify a value of $10, relief would probably have to generate revenue of nearly $700 per patient, for EACH and EVERY of the potential 38 million, and that's being generous. A look at reliefs financials is best left for the halloween season...

https://finance.yahoo.com/quote/RLFTF/financials/

Spooky. So it's not the greatest investment (quite a kind assessment), but how about as a treatment for Covid-19 ARDS?

Quote:

intravenous aviptadil, administered as 3 successive 12 hour infusions of 50/100/150 pmol/kg/hr



An army of nurses and attendents would be needed to administer.. guess it could be better than nothing. Possibly.




(1)
(0)




Mondobiotech Holding AG Basel (RLFTF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us